The Food and Drug Administration (FDA) has approved inhibitors for the first‐line treatment of NSCLC with EGFR, ALK, ROS1, RET, MET, BRAF, and NTRK alterations. The gene discussed is RET; the disease is non-small cell lung carcinoma.